Targeting WDR5: A WINning Anti-Cancer Strategy?

• Main Authors: Erin R Aho, April M Weissmiller, Stephen W Fesik, William P Tansey
• Format: Article
• Language: English
• Published: SAGE Publishing 2019-07-01
• Series: Epigenetics Insights
• Online Access: https://doi.org/10.1177/2516865719865282

WDR5 is a component of multiple epigenetic regulatory complexes, including the mixed lineage leukemia (MLL)/SET complexes that deposit histone H3 lysine 4 methylation. Inhibitors of an arginine-binding cavity in WDR5, known as the W DR5- in teraction (WIN) site, have been proposed to selectively kill MLL-rearranged malignancies via an epigenetic mechanism. We discovered potent WIN site inhibitors and found that they kill MLL cancer cells not through changes in histone methylation, but by displacing WDR5 from chromatin at protein synthesis genes, choking the translational capacity of these cells, and inducing death via a nucleolar stress response. The mechanism of action of WIN site inhibitors reveals new aspects of WDR5 function and forecasts broad therapeutic utility as anti-cancer agents.